MedPath

Fluticasone Propionate and Formoterol Fumarate

Generic Name
Fluticasone Propionate and Formoterol Fumarate

Overview

No overview information available.

Indication

用于治疗哮喘。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
Flutiform® Compared With Seretide® in the Treatment of COPD
2014/07/21
NCT02195375
Phase 2
Completed
Mundipharma Research Limited
Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.
2014/02/14
NCT02063139
Phase 2
Completed
Mundipharma Research Limited
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
2013/09/19
NCT01946620
Phase 3
Completed
Mundipharma Research Limited
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients
2012/01/18
NCT01511367
Phase 3
Completed
Mundipharma Research Limited
Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma
2010/04/07
NCT01099722
Phase 3
Completed
Mundipharma Research Limited
Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma
2008/08/14
NCT00734318
Phase 3
Completed
Mundipharma Research Limited
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
2008/04/14
NCT00657774
Phase 1
Completed
SkyePharma AG
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
2008/04/01
NCT00649025
Phase 3
Completed
SkyePharma AG
An Open, Randomised, Parallel Group Multicentre Study to Compare the Efficacy and Safety of Flutiform® pMDI vs Fluticasone pMDI Plus Formoterol DPI in Adolescent and Adult Subjects With Mild to Moderate-severe Persistent, Reversible Asthma
2007/11/26
NCT00563056
Phase 3
Completed
Mundipharma Research Limited
Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma
2007/05/21
NCT00476073
Phase 3
Completed
Mundipharma Research Limited

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Fluticasone Propionate and Formoterol Fumarate Aerosol for Inhalation
NAPP PHARMACEUTICALS LIMITED
国药准字HJ20230108
化学药品
吸入气雾剂
9/12/2023
Fluticasone Propionate and Formoterol Fumarate Aerosol for Inhalation
NAPP PHARMACEUTICALS LIMITED
国药准字HJ20230106
化学药品
吸入气雾剂
9/12/2023
Fluticasone Propionate and Formoterol Fumarate Aerosol for Inhalation
NAPP PHARMACEUTICALS LIMITED
国药准字HJ20230107
化学药品
吸入气雾剂
9/12/2023

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy